Health Condition 1: N186- End stage renal disease Health Condition 2: N186- End stage renal disease Health Condition 3: N186- End stage renal disease Health Condition 4: N186- End stage renal disease Health Condition 5: N186- End stage renal disease
Conditions
Interventions
None listed
Sponsors
IQRAA INTERNATIONAL HOSPITAL AND RESEARCH CENTER
Eligibility
Inclusion criteria
Inclusion criteria: First objective- All pre and post-renal transplant patients willing to participate in the study. Second objective- patients found to be extensive metabolizer for tacrolimus on genotyping.
Exclusion criteria
Exclusion criteria: Patients not willing/cooperative for the study. Patients who are on other drugs which interfere with the tacrolimus level. Patients with abnormal LFT and patients who are not available for follow up.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Assessment of pharmacokinetic, and pharmacodynamic actions of the drug among extensive metabolizers Timepoint: Between two patient visits with an interval of one month. | — |
Secondary
| Measure | Time frame |
|---|---|
| Tacrolimus maximum blood levelsTimepoint: will be measured 1.5 hours after the dose administration. | — |
Countries
India
Contacts
Public ContactRatheeshkumar NM
Lovely Professional University
Outcome results
None listed